4 Healthcare Stock Stories for Your Medical Portfolio Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Closing price $36.27

On Thursday, Isis said that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMN in children suffering from spinal muscular atrophy, show that the majority of SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests as long as 14 months following a single injection of the drug. The Phase 1 data, including these preliminary follow-on data, will be presented at the International Congress of the World Muscle Society by Dr. Kathy Swoboda on October 3. Spinal muscular atrophy is a severe and rare genetic neuromuscular disease described by muscle atrophy and weakness and is the most common genetic cause of infant mortality.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business